Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Interesting..

<< Previous

Bullboard Posts

Next >>

Comment by westcoast1000on Mar 16, 2023 5:22pm

133 Views

Post# 35343639

RE:RE:Interesting..

I reviewed the new presentation and it has much more discussion about CAR-T and pela, IIRC. As always the information is clear and impressive. They do a veyr good job communicating complex science and health questions.

However, the term "potential" biomarker is still apparent on page 12.

<< Previous

Bullboard Posts

Next >>

Near-term and long-term outlook for gold